col blocks we are bridge builder col blocks
COVID Antworten in den wissenschaftlichen Zeitschriften der Welt


16 Ergebisse       Seite 1

 [1] 
Springer-Verlag: Medicinal Chemistry Research
  Original Artikel Datum Titel Autoren   Alle Autoren
1 [GO] 2025―Feb―23 An evaluation of spirooxindoles as blocking agents of SARS-CoV-2 spike/ACE2 interaction: synthesis, biological evaluation and computational analysis Albert Enama Ehinak, Maloba M. M. Lobe, Donatus B. Eni, Conrad V. Simoben, Ian Tietjen, Mathieu J. Mbenga Tjegbe, et al. (+6)
2 [GO] 2024―Nov―14 Inhibition of SARS-CoV-2 replication in cells by G-quadruplex ligands Dehua Luo, Chenxi Liu, Elishiba Muturi, Zhe Hu, Wei Hong, Chao Gao, et al. (+4)
3 [GO] 2024―Jul―14 Potential therapeutic effects of ester derivatives of Ribavirin against SARS-CoV-2 Aaminat Qureshi, Samina Bano
4 [GO] 2024―Jun―26 Design and synthesis of diphenyl-1H-imidazole analogs targeting Mpro/3CLpro enzyme of SARS-CoV-2 Ashish M. Kanhed, Amisha Vora, Ami Thakkar, Gudepalya Renukaiah Rudramurthy, Radha Krishan Shandil, Rajappa Harisha, et al. (+2)
5 [GO] 2024―Mai―28 Exploring nucleoside analogs: key targets in the viral life cycle - advancing strategies against SARS-CoV-2 Roopal Garg, Raveen Kumar, Ritika Srivastava, Richa Srivastava
6 [GO] 2024―Mrz―05 Design, synthesis, and biochemical and computational screening of novel oxindole derivatives as inhibitors of Aurora A kinase and SARS-CoV-2 spike/host ACE2 interaction Donatus B. Eni, Joel Cassel, Cyril T. Namba-Nzanguim, Conrad V. Simoben, Ian Tietjen, Ravikumar Akunuri, et al. (+2)
7 [GO] 2023―Dez―11 Computer-aided design, synthesis and evaluation of new SARS-CoV-2 Mpro inhibitors based on 1,5,6,7-tetrahydro-4H-indazol-4-one scaffold Yuri A. Piven, Veronica G. Zinovich, Dmitriy N. Shcherbakov, Varvara Yu. Chirkova, Svetlana V. Belenkaya, Raman M. Puzanau, et al. (+2)
8 [GO] 2023―Aug―10 Synthesis of indole-based ferulic acid derivatives and in vitro evaluation of antiviral activity against SARS-CoV-2 Marina Mol S. A. Verzola, Daisymara Priscila de Almeida Marques, Elany Barbosa da Silva, Mateus Sá Magalhães Serafim, Rafaela Salgado Ferreira, Pavla Fajtová, et al. (+5)
9 [GO] 2023―Jul―05 SARS-CoV-2 3CL-protease inhibitors derived from ML300: investigation of P1 and replacements of the 1,2,3-benzotriazole Alice Hooper, Jonathan D. Macdonald, Brenna Reilly, Joshua Maw, Aidan P. Wirrick, Sang Hoon Han, et al. (+6)
10 [GO] 2022―Aug―30 The history, mechanism, and perspectives of nirmatrelvir (PF-07321332): an orally bioavailable main protease inhibitor used in combination with ritonavir to reduce COVID-19-related hospitalizations Ryan P. Joyce, Vivian W. Hu, Jun Wang
11 [GO] 2022―Mai―12 Invalidation of dieckol and 1,2,3,4,6-pentagalloylglucose (PGG) as SARS-CoV-2 main protease inhibitors and the discovery of PGG as a papain-like protease inhibitor Haozhou Tan, Chunlong Ma, Jun Wang
12 [GO] 2022―Jan―03 Review on molnupiravir as a promising oral drug for the treatment of COVID-19 Elham Zarenezhad, Mahrokh Marzi
13 [GO] 2021―Dez―02 A review of natural products, their effects on SARS-CoV-2 and their utility as lead compounds in the discovery of drugs for the treatment of COVID-19 Robert L. Chapman, Shridhar V. Andurkar
14 [GO] 2021―Feb―05 Structural modeling and analysis of the SARS-CoV-2 cell entry inhibitor camostat bound to the trypsin-like protease TMPRSS2 Diego E. Escalante, David M. Ferguson
15 [GO] 2020―Sep―10 What are the drugs having potential against COVID-19? Kaan Kucukoglu, Nagihan Faydalı, Dilek Bul
16 [GO] 2020―Jul―31 Genomics insights of SARS-CoV-2 (COVID-19) into target-based drug discovery P. Chellapandi, S. Saranya
 [1] 

16 Ergebisse       Seite 1


[de][en]

Letzte Änderung 2023―Okt―27 12:08:13 UTC

© Daten-Quadrat 2022       Done in 0.004 sec